5FU infusion with mitomycin-C versus 5FU infusion with methyl-CCNU in the treatment of advanced colon cancer.A southwest oncology group study
- 31 August 1978
- Vol. 42 (3) , 1228-1233
- https://doi.org/10.1002/1097-0142(197809)42:3<1228::aid-cncr2820420330>3.0.co;2-s
Abstract
The Southwest Oncology Group (SWOG) in a randomized trial evaluated 5FU infusions in combination with either Mitomycin-C or Methyl-CCNU in patients with disseminated large bowel cancer. A response rate of 18% was noted on the 5FU-Mitomycin limb as compared to 16% on the Methyl-CCNU arm (p = .39). Median survival for all treated patients was 43 weeks on both arms. Myelosuppression was found to be more significant on the Mitomycin-C arm. Regression analysis demonstrated that performance status, sex, and primary site were significant pretreatment characteristics for predicting survival. The response rates associated with this burdensome method of 5FU administration in combination with either Mitomycin-C or Methyl-CCNU appear to offer little advantage over bolus 5FU alone.Keywords
This publication has 6 references indexed in Scilit:
- Mitomycin-C alone and in combination with infused 5-fluorouracil in the treatment of disseminated gastrointestinal carcinomasMedical and Pediatric Oncology, 1978
- Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU.A southwest oncology group studyCancer, 1976
- Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinomaCancer, 1975
- A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: A Southwest oncology group studyCancer, 1975
- The chemotherapy of large-bowel cancer present status and future prospectsDigestive Diseases and Sciences, 1974
- 5-Fluorouracil in Cancer: An Improved RegimenAnnals of Internal Medicine, 1970